Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.8383
-0.0027 (-0.32%)
At close: Oct 9, 2025, 4:00 PM EDT
0.8383
0.00 (0.00%)
After-hours: Oct 9, 2025, 4:00 PM EDT
Xilio Therapeutics Employees
Xilio Therapeutics had 64 employees as of December 31, 2024. The number of employees decreased by 9 or -12.33% compared to the previous year.
Employees
64
Change (1Y)
-9
Growth (1Y)
-12.33%
Revenue / Employee
$234,391
Profits / Employee
-$878,469
Market Cap
43.45M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64 | -9 | -12.33% |
Dec 31, 2023 | 73 | -16 | -17.98% |
Dec 31, 2022 | 89 | 15 | 20.27% |
Dec 31, 2021 | 74 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
XLO News
- 6 days ago - Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - GlobeNewsWire
- 6 days ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - GlobeNewsWire
- 4 months ago - Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewsWire
- 4 months ago - Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering - GlobeNewsWire